Genetic variants in CETP increase risk of intracerebral hemorrhage

In observational epidemiologic studies, higher plasma high‐density lipoprotein cholesterol (HDL‐C) has been associated with increased risk of intracerebral hemorrhage (ICH). DNA sequence variants that decrease cholesteryl ester transfer protein (CETP) gene activity increase plasma HDL‐C; as such, medicines that inhibit CETP and raise HDL‐C are in clinical development. Here, we test the hypothesis that CETP DNA sequence variants associated with higher HDL‐C also increase risk for ICH.

[1]  Avraham Z Cooper.  Lacunar , 2018, Journal of General Internal Medicine.

[2]  S. Greenberg,et al.  Subacute decline in serum lipids precedes the occurrence of primary intracerebral hemorrhage , 2016, Neurology.

[3]  D. Tousoulis,et al.  HDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation , 2016, Expert opinion on therapeutic targets.

[4]  V. Montori,et al.  Predicting the Overuse of PCSK-9 Inhibitors. , 2015, JAMA.

[5]  Margaret A. Pericak-Vance,et al.  Estimating cumulative pathway effects on risk for age-related macular degeneration using mixed linear models , 2015, BMC Bioinformatics.

[6]  S. Greenberg,et al.  APOE ε4 and lipid levels affect risk of recurrent nonlobar intracerebral hemorrhage , 2015, Neurology.

[7]  V. Gudnason,et al.  Risk Factors Associated With Incident Cerebral Microbleeds According to Location in Older People: The Age, Gene/Environment Susceptibility (AGES)-Reykjavik Study. , 2015, JAMA neurology.

[8]  J. Kastelein,et al.  Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study , 2015, The Lancet.

[9]  P. Wolf,et al.  Lipid and lipoprotein measurements and the risk of ischemic vascular events , 2015, Neurology.

[10]  A. Gotto,et al.  Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial. , 2015, Journal of clinical lipidology.

[11]  S. Kathiresan,et al.  Multiple Associated Variants Increase the Heritability Explained for Plasma Lipids and Coronary Artery Disease , 2014, Circulation. Cardiovascular genetics.

[12]  D. Rader,et al.  HDL and cardiovascular disease , 2014, The Lancet.

[13]  Lacunar Strokes in Patients With Diabetes Mellitus: Risk Factors, Infarct Location, and Prognosis The Secondary Prevention of Small Subcortical Strokes Study , 2014, Stroke.

[14]  Lisa J. Martin,et al.  Meta-analysis of genome-wide association studies identifies 1q22 as a susceptibility locus for intracerebral hemorrhage. , 2014, American journal of human genetics.

[15]  Tanya M. Teslovich,et al.  Discovery and refinement of loci associated with lipid levels , 2013, Nature Genetics.

[16]  M. Malkoff,et al.  The Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH) Study Protocol , 2013, Stroke.

[17]  Xiang Wang,et al.  Cholesterol Levels and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis , 2013, Stroke.

[18]  Sohail Asghar,et al.  A REVIEW OF FEATURE SELECTION TECHNIQUES IN STRUCTURE LEARNING , 2013 .

[19]  J. Ioannidis,et al.  Meta-analysis methods for genome-wide association studies and beyond , 2013, Nature Reviews Genetics.

[20]  F. Akhlaghi,et al.  Future of Cholesteryl Ester Transfer Protein (CETP) Inhibitors: A Pharmacological Perspective , 2013, Clinical Pharmacokinetics.

[21]  K. Williams,et al.  Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. , 2012, Journal of the American College of Cardiology.

[22]  J. Broderick,et al.  Risk factors for intracerebral hemorrhage differ according to hemorrhage location , 2012, Neurology.

[23]  Ian J Deary,et al.  Cohort profile: the Lothian Birth Cohorts of 1921 and 1936. , 2012, International journal of epidemiology.

[24]  D. Johns,et al.  On-and Off-Target Pharmacology of Torcetrapib , 2012, Drugs.

[25]  Tom R. Gaunt,et al.  Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. , 2012, American journal of human genetics.

[26]  P. Barter,et al.  Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk , 2012, Journal of Lipid Research.

[27]  John Spertus,et al.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.

[28]  Robert J. van Oostenbrugge,et al.  Vascular inflammation in cerebral small vessel disease , 2012, Neurobiology of Aging.

[29]  W. Hörl,et al.  Serum amyloid A in uremic HDL promotes inflammation. , 2012, Journal of the American Society of Nephrology : JASN.

[30]  P. Koudstaal,et al.  International Epidemiology of Intracerebral Hemorrhage , 2012, Current Atherosclerosis Reports.

[31]  J. Marchini,et al.  Genotype Imputation with Thousands of Genomes , 2011, G3: Genes | Genomes | Genetics.

[32]  D. Rader,et al.  Novel HDL-directed pharmacotherapeutic strategies , 2011, Nature Reviews Cardiology.

[33]  Yan V. Sun,et al.  A Bivariate Genome-Wide Approach to Metabolic Syndrome , 2011, Diabetes.

[34]  Hong-Wen Deng,et al.  Analyses and Comparison of Imputation-Based Association Methods , 2010, PloS one.

[35]  David H. Alexander,et al.  Fast model-based estimation of ancestry in unrelated individuals. , 2009, Genome research.

[36]  M. Vermeulen,et al.  HEMORRHAGIC STROKE IN THE STROKE PREVENTION BY AGGRESSIVE REDUCTION IN CHOLESTEROL LEVELS STUDY , 2009, Neurology.

[37]  L. Mascitelli,et al.  HEMORRHAGIC STROKE IN THE STROKE PREVENTION BY AGGRESSIVE REDUCTION IN CHOLESTEROL LEVELS STUDY , 2009, Neurology.

[38]  R. Collins,et al.  Common variants at 30 loci contribute to polygenic dyslipidemia , 2009, Nature Genetics.

[39]  D. Siscovick,et al.  Cholesteryl Ester Transfer Protein (CETP) Genetic Variation and Early Onset of Non‐Fatal Myocardial Infarction , 2008, Annals of human genetics.

[40]  J. Danesh,et al.  Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. , 2008, JAMA.

[41]  P. Jones,et al.  Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit , 2008, Cardiovascular Drugs and Therapy.

[42]  Philippe Froguel,et al.  Common genetic variation near MC4R is associated with waist circumference and insulin resistance , 2008, Nature Genetics.

[43]  M. Hennerici,et al.  Effects of Intense Low-Density Lipoprotein Cholesterol Reduction in Patients With Stroke or Transient Ischemic Attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial , 2007, Stroke.

[44]  Pedro Larrañaga,et al.  A review of feature selection techniques in bioinformatics , 2007, Bioinform..

[45]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[46]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[47]  R. Collins,et al.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions , 2004, The Lancet.

[48]  J. Holmes,et al.  Lifetime cost of stroke in the United States. , 1996, Stroke.

[49]  N. Battistini,et al.  Recurrence of bleeding in patients with primary intracerebral hemorrhage. , 1995, Stroke.